Using Effectiveness and Cost-effectiveness to Make Drug Coverage Decisions
Authors:
- Anthony HarrisAHAnthony Harris
- Jing Jing LiJLJing Jing Li
- Karen YongKYKaren Yong
- Karen M. LeeKLKaren M. Lee
- Braden J. MannsBMBraden J. Manns
Top Cited Papers
- 7 October 2009
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 302 (13) , 1437-1443
Abstract
Research from JAMA — Using Effectiveness and Cost-effectiveness to Make Drug Coverage Decisions — A Comparison of Britain, Australia, and CanadaKeywords
This publication has 19 references indexed in Scilit:
- Comparative Effectiveness Research and Evidence‐Based Health Policy: Experience from Four CountriesThe Milbank Quarterly, 2009
- The Role of Value for Money in Public Insurance Coverage Decisions for Drugs in Australia: A Retrospective Analysis 1994-2004Medical Decision Making, 2008
- Optimizing the use of prescription drugs in Canada through the Common Drug ReviewCanadian Medical Association Journal, 2008
- Parliamentary review asks NICE to do better stillBMJ, 2008
- The Common Drug Review: A NICE start for Canada?Health Policy, 2006
- Surrogate Markers in Clinical Studies: Problems Solved or Created?American Journal of Kidney Diseases, 2006
- Centralized Drug Review Processes In Australia, Canada, New Zealand, And The United KingdomHealth Affairs, 2006
- Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective studyBMJ, 2004
- Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysisHealth Economics, 2004
- Problems in Pharmacoeconomic AnalysesJAMA, 2000